Dendritic NanoTechnologies Appoints Dow Chemical Licensing Manager to Board of Directors
In January, DNT announced a strategic partnership with Dow and DNT investor Starpharma. This agreement means that DNT owns the world's broadest dendrimer patent portfolio (196 patents comprising 41 patent families).
"Thanks in part to Mike's efforts while heading technology licensing at Dow, DNT was able to acquire the majority of intellectual property in the dendrimer field," said Robert Berry, chief executive officer, Dendritic NanoTechnologies.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.